Pharmaceutical regulatory data, drug approvals & compliance tracking
Home › Drug Approvals › Dermatology
Access detailed information about dermatology drug approvals. FDA News aggregates data from multiple verified sources to provide actionable insights. Our methodology combines automated data collection with expert curation to ensure high-quality, reliable information. Each data point is verified against multiple sources before publication.
For professional users, our API provides programmatic access to all data shown on this page. Rate limits apply based on your subscription tier. Contact us for enterprise pricing. Regional variations can significantly impact the numbers shown. We recommend filtering by your specific geography for the most relevant insights. Our coverage spans major markets worldwide.
This page is part of the FDA News data platform, which offers comprehensive coverage across related categories. Navigate using the links above to explore other sections.
| Drug Name | Manufacturer | Approval Date | Indication | Type |
|---|---|---|---|---|
| Dermxumab | PharmaCo A | Mar 2026 | Advanced dermatology | Biologic |
| Dermtinib | PharmaCo B | Jan 2026 | Relapsed dermatology | Small molecule |
| Dermlizumab | PharmaCo C | Nov 2025 | Moderate dermatology | Monoclonal Ab |
| Dermstat | PharmaCo D | Sep 2025 | Chronic dermatology | Oral |
| Dermparin | PharmaCo E | Jul 2025 | Acute dermatology | Injectable |
Data updated continuously. Last refresh: May 11, 2026 14:30 UTC.
